Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD- Naive or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies

被引：0

作者：

Husni, M. Elaine ^{[1
]}

Mease, Philip J. ^{[2
,3
]}

Merola, Joseph ^{[4
]}

Behrens, Frank

Favalli, Ennio G. ^{[5
,6
,7
]}

McGonagle, Dennis ^{[8
]}

Tillett, William R. ^{[9
]}

Tsuji, Shigeyoshi ^{[10
]}

Ink, Barbara ^{[11
]}

Bajracharya, Rajan ^{[11
]}

Lambert, Jeremy ^{[12
]}

Coarse, Jason ^{[13
]}

Gossec, Laure ^{[14
,15
]}

机构：

[1] Cleveland Clin, Dept Rheumat & Immunol Dis, Cleveland, OH USA

[2] Swedish Med Center, Providence St Joseph Hlth, Seattle, WA USA

[3] Univ Washington, Sch Med, Seattle, WA USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Newton, MA USA

[5] Goethe Univ, Univ Hosp, Div Rheumatol, Frankfurt, Germany

[6] Fraunhofer Inst Translat Med Pharmacol, Frankfurt, Germany

[7] Univ Milan, ASST Gaetano Pini CTO, Dept Rheumatol, Milan, Italy

[8] Univ Leeds, Leeds Biomed Res Ctr, Leeds, England

[9] Royal Natl Hosp Rheumat Dis, Dept Rheumatol, Bath, England

[10] Nippon Life Hosp, Osaka, Japan

[11] UCB Pharma, Slough, England

[12] UCB Pharma, Irigny, France

[13] UCB Pharma, Morrisville, NY USA

[14] Sorbonne Univ, Paris, France

[15] Hop La Pitie Salpetriere, Paris, France

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

PHASE-3; TRIAL; DOUBLE-BLIND;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0527

引用

页码：1035 / 1038

页数：4

共 50 条

[41] Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients With Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results From a Phase 3B Trial
McInnes, Iain
Sewerin, Philipp
Richard, Nicolas
Sharaf, Mohamed
Efficace, Michela
Shawi, May
Perate, Michelle
Zimmermann, Miriam
Coates, Laura
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 80 - 80
[42] Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
McInnes, Iain B.
Sewerin, Philipp
Sharaf, Mohamed
Efficace, Michela
Shawi, May
Perate, Michelle
Zimmermann, Miriam
Coates, Laura
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4241 - 4244
[43] BIMEKIZUMAB DELIVERED SUSTAINED IMPROVEMENTS IN EFFICACY AND DEMONSTRATED A CONSISTENT SAFETY PROFILE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
Mease, P. J.
Merola, J. F.
Landewe, R.
McInnes, I. B.
Ritchlin, C. T.
Tanaka, Y.
Asahina, A.
Gossec, L.
Ink, B.
Heinrichs, A.
Bajracharya, R.
Shende, V
Coarse, J.
Coates, L. C.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 98 - 99
[44] SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROMTHE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
Coates, L.
Landewe, R. B. M.
Mcinnes, I.
Ritchlin, C. T.
Gottlieb, A. B.
Orbai, A. M.
Warren, R. B.
Ink, B.
Bajracharya, R.
Coarse, J.
Merola, J. F.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1775 - 1776
[45] Bimekizumab-treated patients with active psoriatic arthritis showed sustained achievement of minimal disease activity and remission: Up to 2-year results from two phase 3 studies
Coates, L. C.
Kristensen, L. E.
Ogdie, A.
Tillett, W.
Ink, B.
Goldammer, N.
Bajracharya, R.
Coarse, J.
Orbai, A. M.
SWISS MEDICAL WEEKLY, 2024, 154 : 35S - 35S
[46] EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
Ostor, A.
Van den Bosch, F.
Papp, K.
Asnal, C.
Blanco, R.
Aelion, J.
Alperovich, G.
Zhang, Y.
Wang, Z.
Soliman, A. M.
Eldred, A.
Kivitz, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 138 - 139
[47] Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNFα inhibitor-experienced
Ritchlin, Christopher T.
Helliwell, Philip S.
Boehncke, Wolf-Henning
Soriano, Enrique R.
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Chakravarty, Soumya D.
Zazzetti, Federico
Subramanian, Ramanand A.
Xu, Xie L.
Zuraw, Qing C.
Sheng, Shihong
Jiang, Yusang
Agarwal, Prasheen
Zhou, Bei
Zhuang, Yanli
Shawi, May
Karyekar, Chetan S.
Deodhar, Atul
RMD OPEN, 2021, 7 (01):
[48] Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naive and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Gladman, Dafna
Erik, Lars
Thaci, Diamant
Gisondi, Paolo
Gossec, Laure
Husni, M. Elaine
Gottlieb, Alice
Dobashi, Hiroaki
Ink, Barbara
Assudani, Deepak
Bajracharya, Rajan
Coarse, Jason
Lambert, Jeremy
Tillett, William
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4203 - 4205
[49] Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Merola, Joseph
Landewe, Robert
McInnes, Iain B.
Mease, Philip J.
Ritchlin, Christopher
Tanaka, Yoshiya
Asahina, Akihiko
Behrens, Frank
Gladman, Dafna
Gossec, Laure
Warren, Richard
Ink, Barbara
Assudani, Deepak
Bajracharya, Rajan
Coarse, Jason
Coates, Laura
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3169 - 3171
[50] Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFa inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial (vol 395, pg 1115, 2020)
Deodhar, A.
Helliwell, P. S.
Boehncke, W-H
LANCET, 2020, 395 (10230): : 1114 - 1114

← 1 2 3 4 5 →